You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
ElectronicTextile Antennas
SBC: Applied Radar, Inc. Topic: SB021014Long-duration wide-area surveillance missions increasingly are space-based. MEO orbits offer space-based radar systems more time on station, but require very large array apertures on the order of 100m in diameter. Achieving larger apertures with smaller, lighter launch packages and stable on-orbit pointing is a challenge that E-Textiles promises to meet. Textile processes can be used to achieve a ...
SBIR Phase II 2008 Department of DefenseArmy -
Expanding small molecule functional metagenomics through shuttle BAC expression i
SBC: INTACT GENOMICS INC Topic: NIAIDDESCRIPTION provided by applicant Hospital acquired microbial infections are the fourth largest killer in America taking lives and adding $ B to hospital costs The emergence of drug resistant microbes has further amplified public health concern Fungi are prolific producers of anti microbial secondary metabolites SM and since the turn of the century have provided of bioactive m ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Biological vector control reducing arboviruses, including Dengue and Chikungunya
SBC: MosquitoMate, Inc Topic: NIAIDDESCRIPTION provided by applicant In the absence of effective approved drugs or vaccines vector control remains the only means of intervention for many against mosquito borne diseases This problem grows more complex with the recent establishment of multiple exotic mosquito species and mosquito borne pathogens Furthermore changing climate conditions are predicted to alter the traditional ra ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer
SBC: APOIMMUNE, INC Topic: N/ADESCRIPTION (provided by applicant): Cervical cancer is one of the most common cancers affecting women and is a worldwide health problem. Unlike most cancers, cervical cancer is caused by a virus - the human papillomavirus (HPV). Two preventative vaccines against HPV were recently licensed in the United States. Merck and Co. developed a vaccine called Gardasil(tm) and GlaxoSmithKline has develop ...
SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
THERAPEUTIC USE OF INTER-ALPHA INHIBITOR IN SEPSIS
SBC: PROTHERA BIOLOGICS, INC. Topic: N/ADESCRIPTION (provided by applicant): The goal of the proposed research is to demonstrate that Inter-alpha serine protease inhibitor proteins (IaIp) are an effective therapy for sepsis. In sepsis, normally high plasma levels of IaIp drop dramatically in
SBIR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
Air-transportable, Rapid Production Mixed-base Hydrogen Peroxide System
SBC: VITOK ENGINEERS INC Topic: MDA02046The utilization of Mixed Base Hydrogen Peroxide is well documented in its application for the COIL and ABL Systems. During Phase I, VITOK determined a variety of recipes that could be utilized with the mixing of caustics and H2O2 while developing them in a system that is portable, air-transportable, supportable with a small logistics footprint. Initial essential design of the general skid arrang ...
SBIR Phase II 2004 Department of DefenseMissile Defense Agency -
Therapy and Prophylaxis for Genital Tract Infection
SBC: THERAPYX, INC. Topic: NIAIDDESCRIPTION provided by applicant Genital tract infection with Neisseria gonorrhoeae gonorrhea does not induce a state of specific protective immunity and can be acquired repeatedly Despite public health measures the disease persists at an unacceptably high frequency there is no vaccine against it and resistance even to the latest generations of antibiotics continues to emerge Recent fin ...
SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a Counterpulsation Therapy Device
SBC: SCR, INC. Topic: N/ADESCRIPTION (provided by applicant): SCR, Inc. (Louisville, KY) has developed a long-term implantable counterpulsation device (CPD) to treat heart failure (HF) patients who may be responsive to a milder form of cardiac assist. The CPD is 32-ml stroke vol ume, valveless pneumatically-driven blood sac with a single inflow/outflow cannula. The sac fits ergonomically in a pacemaker pocket' and the ...
SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Stem Cell Graft Engineering to Treat Sickle Cell Disease
SBC: REGENEREX, LLC Topic: N/ADESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is a genetic abnormality of red blood cells (RBC) that affects over 70,000 people in the United States, or approximately 1 in every 500 African-Americans. With current therapies, the mortality in the United States is 50% by age 40. SCD is a chronic, debilitating disease associated with frequent painful crises, acute chest syndrome, st ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Development of a Personalized Medicine Interface for the Safe and Effective Treat
SBC: PHARMACOGENETICS DIAGNOSTIC LABORATORIES Topic: N/ADESCRIPTION (provided by applicant): Warfarin is the most commonly used oral anticoagulant medication. Because an individual's proper warfarin dose is difficult to assess, most physicians initiate therapy at a standard dose and follow up with an INR blood test to ensure the medicine is working properly. Unfortunately, therapeutic warfarin doses vary significantly from patient to patient, so that ...
SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health